Giant Cell Arteritis
A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed)
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (11)
Phase 2 trials (12)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (29)
- Abbott
- AbbVie
- Regeneron
- Bristol-Myers Squibb
- Schering-Plough
- Sanofi
- GlaxoSmithKline
- Mundipharma
- University of Pennsylvania
- University of Groningen
- University of South Florida
- Utrecht University
- University of Bristol
- University of Copenhagen
- University of Western Brittany
- University of Limoges
- University of Toulouse
- Medical University of Vienna
- University of Paris
- Valenciennes Hospital Centre
- Central Hospital Saint Quentin
- Dutch Health Care Insurance Board
- Rouen Normandy University
- University of Burgundy
- University of Picardie Jules Verne
- The Cleveland Clinic
- Reumafonds
- ZGT Almelo
- University of Cantabria
Organization Involved with Phase 2 Indications (18)
- Centocor
- Eli Lilly
- Genentech
- Novartis
- Analgesic Solutions
- Chugai
- Dinora, Inc.
- National Institutes of Health (NIH)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Rockefeller University
- University of Rochester
- University of Bern
- Mayo Clinic
- Peking University
- CHNO des Quinze-Vingts
- Janssen Pharmaceutica NV
- PharPoint Research, Inc.
- Kiniksa Pharmaceuticals, Ltd.
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (2)